Israa Al-ani - Academia.edu (original) (raw)

Papers by Israa Al-ani

Pharmacia/Farmaciâ, Jan 25, 2024

Pharmacia/Farmaciâ, Jan 25, 2024

Pharmaceuticals, Jun 13, 2024

Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSC... more Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSCLC). The aim of this study is to unlock some of the physicochemical properties of ALBHCL that serve as a database for any future studies. A solubility study of ALBHCL was performed in different solvents. Also, photostability was tested in the solution and solid states, and the order of reaction and rate constant were calculated. In addition to the pH solubility relation, the pH-rate relation at different temperatures was also studied, and the profiles were constructed. A solubility study was also performed in different media for the purpose of optimizing suitable sink conditions for the in vitro dissolution testing of solid dosage forms. Solubility tests in multiple solvents and pH conditions revealed that the highest solubility was in DMSO, methanol, and chloroform, with acidic media yielding the maximum solubility but degrading at rather low pH levels. ALBHCL proved unstable at high temperatures and under light exposure, with varying stability across different pH levels. The optimal dissolution media for in vitro oral dosage form evaluation were determined, achieving sink conditions at pH levels of 6.8 and 4.5 with specific additives. This study enhances the existing database on ALBHCL’s physicochemical properties, emphasizing the importance of pH optimization in pharmaceutical processes and providing valuable insights into its pharmaceutical application.

Journal of applied pharmaceutical science, 2014

Jordan journal of pharmaceutical sciences, Mar 19, 2024

Grapefruit is a citrus fruit that belongs to the Rutaceae family. One large grapefruit yields aro... more Grapefruit is a citrus fruit that belongs to the Rutaceae family. One large grapefruit yields around 200–250 ml
of juice, consumed regularly by many individuals owing to its nutritional value, including fiber, vitamin C, and
antioxidants. Grapefruit juice (GFJ) compounds, mainly naringin, bergamottin, and 6,7-dihydroxybergamottin
(DHB), inhibit intestinal CYP3A4 enzymes, which are mediated by the metabolic processes of many drugs and result
in the interaction between GFJ and drugs that are CYP3A4 substrates when administered concomitantly. GFJ-drug
interaction is affected by several factors, including oral bioavailability, patient vulnerability, and factors related to
GFJ consumption, such as the amount of GFJ consumed and the interval between GFJ and drug administration.
Many drugs from different classes have the potential for interaction, including calcium channel blockers such as
felodipine, statins such as simvastatin, immunosuppressants, benzodiazepines such as midazolam, antihistamines
such as terfenadine, and many other drugs. Pharmacists have a strong medical background that makes them able to
predict grapefruit-drug interactions. Thus, they play a critical role in reducing the risk of GFJ-drug interactions by
advising and educating patients when dispensing prescribed and Over-the-counter (OTC) drugs

TThe current work was aimed at the development of a topical drug delivery system for azelaic acid... more TThe current work was aimed at the development of a topical drug delivery system for
azelaic acid (AzA) for acne treatment. The systems tested for this purpose were deep eutectic systems
(DESs) prepared from choline chloride (CC), malonic acid (MA), and PEG 400. Three CC to MA
and eight different MA: CC: PEG400 ratios were tested. The physical appearance of the tested
formulations ranged from solid and liquid to semisolid. Only those that showed liquid formulations
of suitable viscosity were considered for further investigations. A eutectic mixture made from MA:
CC: PEG400 1:1:6 (MCP 116) showed the best characteristics in terms of viscosity, contact angle,
spreadability, partition coefficient, and in vitro diffusion. Moreover, the MCP116 showed close
rheological properties to the commercially available market lead acne treatment product (Skinorin®).
In addition, the formula showed synergistic antibacterial activity between the MA moiety of the DES
and the AzA. In vitro diffusion studies using polyamide membranes demonstrated superior diffusion
of MCP116 over the pure drug and the commercial product. No signs of skin irritation and edema
were observed when MCP116 was applied to rabbit skin. Additionally, the MCP116 was found to be,
physically and chemically, highly stable at 4, 25, and 40 ◦C for a one-month stability study

Background: Gefitinib (GEF) is a tyrosine kinase inhibitor that has proven good efficacy against ... more Background: Gefitinib (GEF) is a tyrosine kinase inhibitor that has proven good efficacy against Non-small cell Lung Carcinoma (NSCLC). It has low solubility and dissolution rate and low oral bioavailability. This work aimed to improve efficacy by loading on ZSM-5 silica nanoparticles and testing the prepared delivery system on A-549 lung cancer cells. Methods: ZSM-5 was synthesized in the laboratory and different methods of loading GEF on the nanoparticles were used, then the system was characterized by X-ray diffraction, Fourier Transport Infra-Red (FTIR), and drug release and dissolution. Results and conclusion: GEF-loaded nanoparticles (NPs) showed prolonged release of GEF over 12 hours with an improved biological efficacy expressed by the decrease in IC50 compared to free GEF (P < 0.001) using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. Also, there was a significant decrease in migration and colony formation ability of the GEF-loaded NPs on A-549 lung cancer cells. In conclusion, loading GEF onto ZSM-5 NPs resulted in a lower IC50 and improved biological action toward A-549 cells.

Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSC... more Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma
(NSCLC). The aim of this study is to unlock some of the physicochemical properties of ALBHCL that
serve as a database for any future studies. A solubility study of ALBHCL was performed in different
solvents. Also, photostability was tested in the solution and solid states, and the order of reaction
and rate constant were calculated. In addition to the pH solubility relation, the pH-rate relation at
different temperatures was also studied, and the profiles were constructed. A solubility study was also
performed in different media for the purpose of optimizing suitable sink conditions for the in vitro
dissolution testing of solid dosage forms. Solubility tests in multiple solvents and pH conditions
revealed that the highest solubility was in DMSO, methanol, and chloroform, with acidic media
yielding the maximum solubility but degrading at rather low pH levels. ALBHCL proved unstable
at high temperatures and under light exposure, with varying stability across different pH levels.
The optimal dissolution media for in vitro oral dosage form evaluation were determined, achieving
sink conditions at pH levels of 6.8 and 4.5 with specific additives. This study enhances the existing
database on ALBHCL’s physicochemical properties, emphasizing the importance of pH optimization
in pharmaceutical processes and providing valuable insights into its pharmaceutical application.

t: This study aims to improve the solubility and dissolution rate of alectinib (ALB), a tyrosine ... more t: This study aims to improve the solubility and dissolution rate of alectinib (ALB), a tyrosine kinase
inhibitor commonly used for treating non-small-cell carcinoma (NSCLC). Given ALB’s low solubility and
bioavailability, complexation with β-cyclodextrin (βCD) and hydroxy propyl β-cyclodextrin (HPβCD)
was evaluated. Some of the different preparation methods used with varying ALB-to-CD ratios led to the
formation of complexes that were characterized using Fourier-Transform Infrared (FTIR) techniques and
Differential Scanning Calorimetry (DSC) to prove complex formation. The encapsulation efficiency was
also determined. The simulations were carried out for ALB’s interactions with βCD and HPβCD. This
study identified the most soluble complex (ALB–HPβCD; 1:2 ratio) and evaluated its dissolution. The
bioavailability of the ALB–HPβCD complex was evaluated in Wistar rats relative to free ALB. Pharmacokinetic profiles revealed increased Cmax (240 ± 26.95 ng/mL to 474 ± 50.07 ng/mL) and AUC0-48
(5946.75 ± 265 ng.h/mL to 10520 ± 310 ng.h/mL) with no change in the elimination rate constant. In
conclusion, the complexation of ALB–HPβCD manages to increase in vitro solubility, the dissolution rate,
and oral bioavailability, providing a favorable approach to improving ALB administration.

International journal of Pharmacy and Pharmaceutical Sciences, Aug 31, 2014

In previous work, Prifinium Bromide had been successfully formulated as oro-dispersible tablets. ... more In previous work, Prifinium Bromide had been successfully formulated as oro-dispersible tablets. However, Prifinium Bromide, a quaternary ammonium compound, has a bitter taste; therefore, taste masking was necessary to produce acceptable oro-dispersible tablets and enhance patients' compliance. Methods: In this work, several attempts had been made to mask the bitterness of this drug. β-cyclodextrin inclusion complexes, solid dispersions of the drug in ethyl cellulose and methyl cellulose as well as loading the drug on Eudragit E100 have all been used. The selected granules were used to prepare oro-dispersible tablets and were evaluated. Results: Drug-Eudragit granules E3 prepared by mass extrusion method gave less than 10% of drug in simulated saliva fluid and almost complete release in simulated gastric fluid after 2 minutes. Therefore, it was used to prepare oro-dispersible tablets formulas. In vitro disintegration time of formula T2 was 45.5 ± 7.7 seconds showed a complete drug release of Prifinium Bromide in phosphate buffer (pH 6.8) and (94%) in SGF (pH 2.1). Conclusion: Loading of Prifinium Bromide on Eudragit E100 using mass extrusion method was the best method to overcome the disagreeable taste of the drug. They gave the least amount of drug released in simulated saliva fluid and passed the quality control tests of tablets after formulation as oro-dispersible tablets. They also gave good taste when tested in vivo.

Journal of Developing Drugs, May 11, 2016

Biomedical and Pharmacology Journal, Mar 25, 2020

Autism spectrum disorder" refers to a range of conditions characterized by challenges with social... more Autism spectrum disorder" refers to a range of conditions characterized by challenges with social skills, repetitive behaviors, speech and nonverbal communication. This study aimed to measure the fasting serum levels of glucose, zinc , copper, zinc / copper ratio and their correlations to the measured lipid profile in matched Non-Autistic by age, gender and body mass index with Autistic patients in Jordan. To find a correlations between the studied parameters that might help in understanding the biochemical changes that may lead to autism also to open away for medical management and treatment of autism. Fasting blood samples were taken from both matched groups (35 each with age 4-12 years) then analyzed the above parameters and data was treated statistically by SPPS while Correlations were determined by Pearson's test. The study revealed that there was significant changes in levels and correlations especially in zinc and zinc/copper ratio in relation to triglycerides and high density lipoprotein in autistic patients.

International journal of drug delivery technology, Jun 30, 2022

Carvedilol is a non-selective beta/alpha1 blocker that is broadly used in treatment of arrhythmia... more Carvedilol is a non-selective beta/alpha1 blocker that is broadly used in treatment of arrhythmia, congestive heart failure, hypertension, and myocardial infarction. Enhancing carvedilol low solubility and dissolution rate would help in improving the efficiency of the tablet dosage form. In this study, different types of silica nanoparticle (NPs) (SBA-16, MCM-41 and ZSM-5) were synthesized. Coupling of SBA-16 with 3-Aminopropyl-triethoxysilane (APTES) was performed to improve surface characteristics of SBA-16. Different methods to load carvedilol on these carriers were used with high-performance liquid chromatography (HPLC) as a method of analysis for carvedilol. For the characterization of the loaded NPs Fourier-transform infrared spectroscopy (FT-IR), X-ray crystallography (XRD) and Therapeutic goods administration (TGA) were used. MCM-41 loaded with Carvedilol was decided to be formulated as tablet dosage and compared with tablets contain carvedilol without carrier. The results showed that SBA-16, SBA-16 coupled, ZSM-5 and MCM-41 carriers were used successfully to load carvedilol in a good drug load percent of 64.5, 69.3, 82 and 90%, respectively. MCM-41 gave highest loading efficiency of carvedilol using solvent evaporation method and the dissolution of carvedilol from powder was superior to the pure carvedilol where it gave 100% release of the drug at 15 minutes compared to 30% of pure carvedilol. MCM-41 loaded with carvedilol was successfully formulated as tablet dosage form according to the specifications of USP and the release of carvedilol from the prepared tablet was 99% at 15 min compared to the carvedilol released from tablets prepared using carvedilol powder which gave 38% which indicates the efficiency of the carrier in increasing the solubility and dissolution of carvedilol, a class II BCS drugs.

journal of applied pharmaceutical science, 2016

Metformin is widely used for type II diabetes. Sugar replacement sweeteners such as Aspartame and... more Metformin is widely used for type II diabetes. Sugar replacement sweeteners such as Aspartame and Stevia, are usually consumed concomitantly with other antidiabetics by patients The aim of this work is to investigate possible effects of two types of sweeteners; stevia and aspartame on the pharmacokinetic parameters of metformin in rats. A simple, validated bio-analytical HPLC method was developed to measure metformin in rat plasma. Three groups of rats, each of eight were subjected to this study. The first group was given metformin solution 20mg/kg alone, the second group was given 20 mg/kg metformin with 4mg/kg stevia and the third group was given 20 mg/kg metformin with 10 mg/kg aspartame on fasting state. Blood samples were taken on scheduled time interval up to 6 hours and analyzed for metformin concentration. Pharmacokinetic parameters were calculated by Non-Compartmental Model and data were interpreted. The results showed that administration of these two sweeteners did not have high effect on pharmacokinetics of metformin.

International Journal of Drug Development and Research, Mar 20, 2018

Pharmaceutica Analytica Acta, Apr 16, 2015

Pharmaceutical Chemistry Journal, Jul 31, 2021

The purpose of this study was to develop and validate a rapid, simple, easy, and precise high-per... more The purpose of this study was to develop and validate a rapid, simple, easy, and precise high-performance liquid chromatography (HPLC) method with diode array detector (DAD) for the simultaneous determination of canagliflozin (CGLN) and metformin (MTFN) in a combined dosage formulation. The chromatographic separation was achieved using a column type Zorbax-x Sβ-C18 (4.6 × 250 mm, 5 μm particle size). Mobile phase consisted of 0.05 M H 3 PO 4 , acetonitrile, and methanol in the 45:45:10 (v/v) ratio. The method was validated as per ICH guidelines in terms of system suitability, ranges, linearity, precision, specificity, accuracy, robustness, limit of quantification (LOQ) and limit of detection (LOD). The retention time (RT, t r ) for MTFN and CGLN were obtained at 8 and 9.45 min, respectively. The calibration curves were found linear in the range of 5 – 100 μg/mL for both drugs in this study, with good correlation coefficients ( R 2 > 0.99898). The suggested design proved to be selective and stability-indicating by the resolution ( R s ) of both analytes as well as by the study of forced-degradation (hydrolysis, oxidation, photolysis, and dry heat) products. The validated HPLC-DAD procedure was profitably tested for the analysis of CGLN and MTFN in their combination pharmaceutical tablet dosage form. In conclusion, a simple selective HPLC-DAD method has been successfully developed and validated for the determination of CGLN and MTFN simultaneously in pharmaceutical dosage form.

Molecules, Jun 22, 2021

This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY

Pharmacia/Farmaciâ, Jan 25, 2024

Pharmacia/Farmaciâ, Jan 25, 2024

Pharmaceuticals, Jun 13, 2024

Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSC... more Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSCLC). The aim of this study is to unlock some of the physicochemical properties of ALBHCL that serve as a database for any future studies. A solubility study of ALBHCL was performed in different solvents. Also, photostability was tested in the solution and solid states, and the order of reaction and rate constant were calculated. In addition to the pH solubility relation, the pH-rate relation at different temperatures was also studied, and the profiles were constructed. A solubility study was also performed in different media for the purpose of optimizing suitable sink conditions for the in vitro dissolution testing of solid dosage forms. Solubility tests in multiple solvents and pH conditions revealed that the highest solubility was in DMSO, methanol, and chloroform, with acidic media yielding the maximum solubility but degrading at rather low pH levels. ALBHCL proved unstable at high temperatures and under light exposure, with varying stability across different pH levels. The optimal dissolution media for in vitro oral dosage form evaluation were determined, achieving sink conditions at pH levels of 6.8 and 4.5 with specific additives. This study enhances the existing database on ALBHCL’s physicochemical properties, emphasizing the importance of pH optimization in pharmaceutical processes and providing valuable insights into its pharmaceutical application.

Journal of applied pharmaceutical science, 2014

Jordan journal of pharmaceutical sciences, Mar 19, 2024

Grapefruit is a citrus fruit that belongs to the Rutaceae family. One large grapefruit yields aro... more Grapefruit is a citrus fruit that belongs to the Rutaceae family. One large grapefruit yields around 200–250 ml
of juice, consumed regularly by many individuals owing to its nutritional value, including fiber, vitamin C, and
antioxidants. Grapefruit juice (GFJ) compounds, mainly naringin, bergamottin, and 6,7-dihydroxybergamottin
(DHB), inhibit intestinal CYP3A4 enzymes, which are mediated by the metabolic processes of many drugs and result
in the interaction between GFJ and drugs that are CYP3A4 substrates when administered concomitantly. GFJ-drug
interaction is affected by several factors, including oral bioavailability, patient vulnerability, and factors related to
GFJ consumption, such as the amount of GFJ consumed and the interval between GFJ and drug administration.
Many drugs from different classes have the potential for interaction, including calcium channel blockers such as
felodipine, statins such as simvastatin, immunosuppressants, benzodiazepines such as midazolam, antihistamines
such as terfenadine, and many other drugs. Pharmacists have a strong medical background that makes them able to
predict grapefruit-drug interactions. Thus, they play a critical role in reducing the risk of GFJ-drug interactions by
advising and educating patients when dispensing prescribed and Over-the-counter (OTC) drugs

TThe current work was aimed at the development of a topical drug delivery system for azelaic acid... more TThe current work was aimed at the development of a topical drug delivery system for
azelaic acid (AzA) for acne treatment. The systems tested for this purpose were deep eutectic systems
(DESs) prepared from choline chloride (CC), malonic acid (MA), and PEG 400. Three CC to MA
and eight different MA: CC: PEG400 ratios were tested. The physical appearance of the tested
formulations ranged from solid and liquid to semisolid. Only those that showed liquid formulations
of suitable viscosity were considered for further investigations. A eutectic mixture made from MA:
CC: PEG400 1:1:6 (MCP 116) showed the best characteristics in terms of viscosity, contact angle,
spreadability, partition coefficient, and in vitro diffusion. Moreover, the MCP116 showed close
rheological properties to the commercially available market lead acne treatment product (Skinorin®).
In addition, the formula showed synergistic antibacterial activity between the MA moiety of the DES
and the AzA. In vitro diffusion studies using polyamide membranes demonstrated superior diffusion
of MCP116 over the pure drug and the commercial product. No signs of skin irritation and edema
were observed when MCP116 was applied to rabbit skin. Additionally, the MCP116 was found to be,
physically and chemically, highly stable at 4, 25, and 40 ◦C for a one-month stability study

Background: Gefitinib (GEF) is a tyrosine kinase inhibitor that has proven good efficacy against ... more Background: Gefitinib (GEF) is a tyrosine kinase inhibitor that has proven good efficacy against Non-small cell Lung Carcinoma (NSCLC). It has low solubility and dissolution rate and low oral bioavailability. This work aimed to improve efficacy by loading on ZSM-5 silica nanoparticles and testing the prepared delivery system on A-549 lung cancer cells. Methods: ZSM-5 was synthesized in the laboratory and different methods of loading GEF on the nanoparticles were used, then the system was characterized by X-ray diffraction, Fourier Transport Infra-Red (FTIR), and drug release and dissolution. Results and conclusion: GEF-loaded nanoparticles (NPs) showed prolonged release of GEF over 12 hours with an improved biological efficacy expressed by the decrease in IC50 compared to free GEF (P < 0.001) using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. Also, there was a significant decrease in migration and colony formation ability of the GEF-loaded NPs on A-549 lung cancer cells. In conclusion, loading GEF onto ZSM-5 NPs resulted in a lower IC50 and improved biological action toward A-549 cells.

Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma (NSC... more Alectinib HCl (ALBHCl) is a tyrosine kinase inhibitor used for non-small cell lung carcinoma
(NSCLC). The aim of this study is to unlock some of the physicochemical properties of ALBHCL that
serve as a database for any future studies. A solubility study of ALBHCL was performed in different
solvents. Also, photostability was tested in the solution and solid states, and the order of reaction
and rate constant were calculated. In addition to the pH solubility relation, the pH-rate relation at
different temperatures was also studied, and the profiles were constructed. A solubility study was also
performed in different media for the purpose of optimizing suitable sink conditions for the in vitro
dissolution testing of solid dosage forms. Solubility tests in multiple solvents and pH conditions
revealed that the highest solubility was in DMSO, methanol, and chloroform, with acidic media
yielding the maximum solubility but degrading at rather low pH levels. ALBHCL proved unstable
at high temperatures and under light exposure, with varying stability across different pH levels.
The optimal dissolution media for in vitro oral dosage form evaluation were determined, achieving
sink conditions at pH levels of 6.8 and 4.5 with specific additives. This study enhances the existing
database on ALBHCL’s physicochemical properties, emphasizing the importance of pH optimization
in pharmaceutical processes and providing valuable insights into its pharmaceutical application.

t: This study aims to improve the solubility and dissolution rate of alectinib (ALB), a tyrosine ... more t: This study aims to improve the solubility and dissolution rate of alectinib (ALB), a tyrosine kinase
inhibitor commonly used for treating non-small-cell carcinoma (NSCLC). Given ALB’s low solubility and
bioavailability, complexation with β-cyclodextrin (βCD) and hydroxy propyl β-cyclodextrin (HPβCD)
was evaluated. Some of the different preparation methods used with varying ALB-to-CD ratios led to the
formation of complexes that were characterized using Fourier-Transform Infrared (FTIR) techniques and
Differential Scanning Calorimetry (DSC) to prove complex formation. The encapsulation efficiency was
also determined. The simulations were carried out for ALB’s interactions with βCD and HPβCD. This
study identified the most soluble complex (ALB–HPβCD; 1:2 ratio) and evaluated its dissolution. The
bioavailability of the ALB–HPβCD complex was evaluated in Wistar rats relative to free ALB. Pharmacokinetic profiles revealed increased Cmax (240 ± 26.95 ng/mL to 474 ± 50.07 ng/mL) and AUC0-48
(5946.75 ± 265 ng.h/mL to 10520 ± 310 ng.h/mL) with no change in the elimination rate constant. In
conclusion, the complexation of ALB–HPβCD manages to increase in vitro solubility, the dissolution rate,
and oral bioavailability, providing a favorable approach to improving ALB administration.

International journal of Pharmacy and Pharmaceutical Sciences, Aug 31, 2014

In previous work, Prifinium Bromide had been successfully formulated as oro-dispersible tablets. ... more In previous work, Prifinium Bromide had been successfully formulated as oro-dispersible tablets. However, Prifinium Bromide, a quaternary ammonium compound, has a bitter taste; therefore, taste masking was necessary to produce acceptable oro-dispersible tablets and enhance patients' compliance. Methods: In this work, several attempts had been made to mask the bitterness of this drug. β-cyclodextrin inclusion complexes, solid dispersions of the drug in ethyl cellulose and methyl cellulose as well as loading the drug on Eudragit E100 have all been used. The selected granules were used to prepare oro-dispersible tablets and were evaluated. Results: Drug-Eudragit granules E3 prepared by mass extrusion method gave less than 10% of drug in simulated saliva fluid and almost complete release in simulated gastric fluid after 2 minutes. Therefore, it was used to prepare oro-dispersible tablets formulas. In vitro disintegration time of formula T2 was 45.5 ± 7.7 seconds showed a complete drug release of Prifinium Bromide in phosphate buffer (pH 6.8) and (94%) in SGF (pH 2.1). Conclusion: Loading of Prifinium Bromide on Eudragit E100 using mass extrusion method was the best method to overcome the disagreeable taste of the drug. They gave the least amount of drug released in simulated saliva fluid and passed the quality control tests of tablets after formulation as oro-dispersible tablets. They also gave good taste when tested in vivo.

Journal of Developing Drugs, May 11, 2016

Biomedical and Pharmacology Journal, Mar 25, 2020

Autism spectrum disorder" refers to a range of conditions characterized by challenges with social... more Autism spectrum disorder" refers to a range of conditions characterized by challenges with social skills, repetitive behaviors, speech and nonverbal communication. This study aimed to measure the fasting serum levels of glucose, zinc , copper, zinc / copper ratio and their correlations to the measured lipid profile in matched Non-Autistic by age, gender and body mass index with Autistic patients in Jordan. To find a correlations between the studied parameters that might help in understanding the biochemical changes that may lead to autism also to open away for medical management and treatment of autism. Fasting blood samples were taken from both matched groups (35 each with age 4-12 years) then analyzed the above parameters and data was treated statistically by SPPS while Correlations were determined by Pearson's test. The study revealed that there was significant changes in levels and correlations especially in zinc and zinc/copper ratio in relation to triglycerides and high density lipoprotein in autistic patients.

International journal of drug delivery technology, Jun 30, 2022

Carvedilol is a non-selective beta/alpha1 blocker that is broadly used in treatment of arrhythmia... more Carvedilol is a non-selective beta/alpha1 blocker that is broadly used in treatment of arrhythmia, congestive heart failure, hypertension, and myocardial infarction. Enhancing carvedilol low solubility and dissolution rate would help in improving the efficiency of the tablet dosage form. In this study, different types of silica nanoparticle (NPs) (SBA-16, MCM-41 and ZSM-5) were synthesized. Coupling of SBA-16 with 3-Aminopropyl-triethoxysilane (APTES) was performed to improve surface characteristics of SBA-16. Different methods to load carvedilol on these carriers were used with high-performance liquid chromatography (HPLC) as a method of analysis for carvedilol. For the characterization of the loaded NPs Fourier-transform infrared spectroscopy (FT-IR), X-ray crystallography (XRD) and Therapeutic goods administration (TGA) were used. MCM-41 loaded with Carvedilol was decided to be formulated as tablet dosage and compared with tablets contain carvedilol without carrier. The results showed that SBA-16, SBA-16 coupled, ZSM-5 and MCM-41 carriers were used successfully to load carvedilol in a good drug load percent of 64.5, 69.3, 82 and 90%, respectively. MCM-41 gave highest loading efficiency of carvedilol using solvent evaporation method and the dissolution of carvedilol from powder was superior to the pure carvedilol where it gave 100% release of the drug at 15 minutes compared to 30% of pure carvedilol. MCM-41 loaded with carvedilol was successfully formulated as tablet dosage form according to the specifications of USP and the release of carvedilol from the prepared tablet was 99% at 15 min compared to the carvedilol released from tablets prepared using carvedilol powder which gave 38% which indicates the efficiency of the carrier in increasing the solubility and dissolution of carvedilol, a class II BCS drugs.

journal of applied pharmaceutical science, 2016

Metformin is widely used for type II diabetes. Sugar replacement sweeteners such as Aspartame and... more Metformin is widely used for type II diabetes. Sugar replacement sweeteners such as Aspartame and Stevia, are usually consumed concomitantly with other antidiabetics by patients The aim of this work is to investigate possible effects of two types of sweeteners; stevia and aspartame on the pharmacokinetic parameters of metformin in rats. A simple, validated bio-analytical HPLC method was developed to measure metformin in rat plasma. Three groups of rats, each of eight were subjected to this study. The first group was given metformin solution 20mg/kg alone, the second group was given 20 mg/kg metformin with 4mg/kg stevia and the third group was given 20 mg/kg metformin with 10 mg/kg aspartame on fasting state. Blood samples were taken on scheduled time interval up to 6 hours and analyzed for metformin concentration. Pharmacokinetic parameters were calculated by Non-Compartmental Model and data were interpreted. The results showed that administration of these two sweeteners did not have high effect on pharmacokinetics of metformin.

International Journal of Drug Development and Research, Mar 20, 2018

Pharmaceutica Analytica Acta, Apr 16, 2015

Pharmaceutical Chemistry Journal, Jul 31, 2021

The purpose of this study was to develop and validate a rapid, simple, easy, and precise high-per... more The purpose of this study was to develop and validate a rapid, simple, easy, and precise high-performance liquid chromatography (HPLC) method with diode array detector (DAD) for the simultaneous determination of canagliflozin (CGLN) and metformin (MTFN) in a combined dosage formulation. The chromatographic separation was achieved using a column type Zorbax-x Sβ-C18 (4.6 × 250 mm, 5 μm particle size). Mobile phase consisted of 0.05 M H 3 PO 4 , acetonitrile, and methanol in the 45:45:10 (v/v) ratio. The method was validated as per ICH guidelines in terms of system suitability, ranges, linearity, precision, specificity, accuracy, robustness, limit of quantification (LOQ) and limit of detection (LOD). The retention time (RT, t r ) for MTFN and CGLN were obtained at 8 and 9.45 min, respectively. The calibration curves were found linear in the range of 5 – 100 μg/mL for both drugs in this study, with good correlation coefficients ( R 2 > 0.99898). The suggested design proved to be selective and stability-indicating by the resolution ( R s ) of both analytes as well as by the study of forced-degradation (hydrolysis, oxidation, photolysis, and dry heat) products. The validated HPLC-DAD procedure was profitably tested for the analysis of CGLN and MTFN in their combination pharmaceutical tablet dosage form. In conclusion, a simple selective HPLC-DAD method has been successfully developed and validated for the determination of CGLN and MTFN simultaneously in pharmaceutical dosage form.

Molecules, Jun 22, 2021

This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY